Skip to main content

Table 2 Demographic and clinical characteristics of responders and non-responders to IFX induction treatment

From: Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience

Characteristics Responders (n = 24) Non-responders (n = 7) p value
Sex (men/women), n (%) 16 (66.7)/8 (33.3) 3 (42.9)/4 (57.1) 0.26
Age (years) 41.8 ± 17.1 48.0 ± 17.8 0.43
Disease duration (years)* 6.5 ± 4.1 9.6 ± 9.2 0.23
Modified Truelove and Witts severity index* 9.7 ± 3.2 10.6 ± 3.4 0.57
Mayo score (endoscopy)* 2.8 ± 0.4 2.9 ± 0.3 0.58
Extent of disease    
  Left-side type, n (%) 12 (50.0) 1 (14.3) 0.09
  Extensive colitis, n (%) 12 (50.0) 6 (85.7)
Concomitant medications    
  Corticoteroids, n (%) 9 (37.5) 1 (14.3) 0.25
  Azathioprine/Mercaptopurine, n (%) 11 (45.8) 4 (57.1) 0.60
  Tacrolimus, n (%) 8 (33.3) 4 (57.1) 0.26
Cytemegalovirus, n (%) 6 (25.0) 4 (57.1) 0.17
Serum hemoglobin level >9.8 g/dl at IFX initiation, n (%) 16 (66.7) 2 (28.6) 0.07
Serum albumin level >35 g/L at IFX initiation, n (%) 12 (50.0) 1 (14.3) 0.21
Serum CRP level <5 mg/L at 2 weeks after IFX initiation, n (%) 18 (75.0) 1 (14.3) 0.006
  1. IFX: infliximab, CRP: C-reactive protein.
  2. Results reported as number (%) of patients or *mean ± standard deviation.